Tofacitinib 5 mg tablet?

Tofacitinib 5 mg tablets are an oral Janus kinase (JAK) inhibitor used to treat several autoimmune conditions. The 5 mg tablet is the standard immediate‑release form; there is also an 11 mg extended‑release (XR) tablet.

Key points:
- Common uses (adults): rheumatoid arthritis (RA), psoriatic arthritis (PsA), and active ulcerative colitis (UC). It may also be used for other approved indications; dosing varies by condition.
- Typical dosing (illustrative, not a substitute for your doctor):
- RA or PsA: usually 5 mg by mouth twice daily (5 mg BID). Some regimens use the 11 mg XR tablet once daily (once-daily dosing varies by country/indication).
- UC: induction with 10 mg twice daily for up to 8 weeks, then maintenance with 5 mg twice daily (regimens can differ by label).
- How to take: with or without food (as directed by your prescriber).
- Important safety considerations:
- Increases risk of infections (including serious infections) and may reactivate latent TB; monitor for signs of infection.
- May raise cholesterol levels and liver enzymes; CBCs and LFTs are typically monitored.
- Rare but serious risks include blood clots at higher doses, malignancies, and gastrointestinal perforation.
- Drugs that suppress the immune system can increase infection risk; avoid live vaccines while taking tofacitinib.
- Pregnancy and breastfeeding: consult a clinician; it can affect fetal development.
- Common side effects: upper respiratory infections, headache, diarrhea, nausea, and redness or bruising at injection sites is not typical for tablets but can occur with immunosuppressants in general.

If you tell me your condition, age, and any other medicines you’re taking, I can tailor the dosing info more specifically. Also, if you’re considering starting or adjusting therapy, please discuss with your healthcare provider or pharmacist.